Emerging Technology Reports

The Emerging Technology Report provides regular updates about emerging and potentially disruptive technologies that are likely to have a significant impact in healthcare. This “early warning” report monitors new health technologies from 6 months to 2 years within a regulatory submission and tracks those as they go through clinical trial development and the regulatory approval process.

For each emerging technology, our analysts describe the technology and intended use, its prospects relative to the regulatory process and FDA information, competing technologies, relevant clinical guidelines, high-level look at the evidence such as published abstracts in the medical literature and available meeting abstracts, and available clinical trials.

Remestemcel-L for Acute Graft-Versus-Host Disease

Remestemcel-L is an allogeneic liquid cell suspension of ex-vivo cultured adult human mesenchymal stem cells derived from healthy donor bone marrow proposed for the treatment of pediatric patients with acute graft-versus-host-disease (aGVHD) refractory to standard first-line steroid therapy.

Reblozyl (Luspatercept) for Beta Thalassemia

Reblozyl is an erythroid maturation agent administered via subcutaneous injection indicated for the treatment of patients with transfusion-dependent beta thalassemia. This recombinant fusion protein is believed to help immature cells develop into red blood cells, thereby preventing anemia and reducing or eliminating the need for frequent blood transfusions.

Vazegepant for Acute Treatment of Migraine

Vazegepant is an intranasal novel small-molecule, calcitonin gene-related peptide (CGRP) receptor antagonist (“gepant”) drug proposed for the acute treatment of migraine headache. CGRP is involved in vasodilation and sensory transmission and is a validated target for the treatment of migraine headache.